1.14
+0.04(+3.64%)
Currency In USD
| Previous Close | 1.1 |
| Open | 1.1 |
| Day High | 1.17 |
| Day Low | 1.1 |
| 52-Week High | 1.89 |
| 52-Week Low | 0.78 |
| Volume | 118,053 |
| Average Volume | 76,617 |
| Market Cap | 19.6M |
| PE | -3.8 |
| EPS | -0.3 |
| Moving Average 50 Days | 1 |
| Moving Average 200 Days | 1.08 |
| Change | 0.04 |
If you invested $1000 in IRIDEX Corporation (IRIX) 10 years ago, it would be worth $124.59 as of December 26, 2025 at a share price of $1.14. Whereas If you bought $1000 worth of IRIDEX Corporation (IRIX) shares 5 years ago, it would be worth $473.03 as of December 26, 2025 at a share price of $1.14.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Iridex Announces the Publication of an Independent Study Demonstrating Safe and Effective Retreatment with Transscleral Laser Treatment Using MicroPulse® Technology in Glaucoma Management
GlobeNewswire Inc.
Dec 11, 2025 12:00 PM GMT
MOUNTAIN VIEW, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retin
Iridex Announces New Thermal Dynamics Study That Strengthens Clinical Foundation and Market Potential of MicroPulse® Technology and Continuous-Wave Laser for Glaucoma Treatment
GlobeNewswire Inc.
Dec 08, 2025 12:00 PM GMT
MOUNTAIN VIEW, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retin
Iridex to Present at the Sidoti Year-End Virtual Investor Conference
GlobeNewswire Inc.
Dec 05, 2025 12:00 PM GMT
MOUNTAIN VIEW, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retin